文献速递妇科

评估患者对高分叶浆液性卵巢癌新型预后基因表达特征可接受性的看法:OTTA-SPOT研究

Evaluating patient perspectives about the acceptability of a novel prognostic gene expression signature for high grade serous ovarian cancer: The OTTA-SPOT study.
PubMed 文献 · Gynecol Oncol · 2025-12-05

本研究纳入澳大利亚或新西兰的33例卵巢癌患者,采用混合方法问卷及焦点小组,了解其对OTTA-SPOT预后基因表达检测优缺点的看法、检测意愿及结果获取偏好。患者认为检测优点大于缺点,88%表示愿意或非常愿意接受检测;定性分析归纳出四个主题,强调实施需以患者为中心并尊重多样偏好。

要点

  • 33例卵巢癌患者中88%愿意或非常愿意接受OTTA-SPOT预后检测。
  • 患者认为该预后检测的潜在优点大于缺点。
  • 实施检测需以患者为中心,兼顾检测引入和结果沟通的多样偏好。

核心结论

  • 卵巢癌患者对预后检测持积极看法;成功实施需采用以患者为中心的方法,兼顾检测引入方式和结果沟通的多样偏好。

研究设计与样本

  • 研究对象为在澳大利亚或新西兰居住、确诊卵巢癌的患者;参与者完成与消费者共同设计的混合方法问卷,并可选择参加1至1.5小时在线焦点小组。

主要发现

  • 33名参与者完成在线问卷;88%表示若该检测可用,愿意或非常愿意接受预后检测。
  • 9名参与者参加焦点小组;主题分析归纳出四个主题:癌症历程与情境、知晓预后的优缺点、何时获取预后信息的复杂性、沟通与服务提供。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumors (OTTA-SPOT) 101 gene expression signature, predicts 5-year survival on a tumor biopsy at diagnosis and identifies the 20 % of patients with a 10 % probability of 5-year survival with standard of care therapy, who may benefit from alternate treatments. This study aims to understand how patients with ovarian cancer perceive the potential advantages and disadvantages of OTTA-SPOT, their willingness for the test, and preferred methods of receiving test results. METHODS: Participants were eligible if they had a diagnosis of ovarian cancer and resided in Australia or New Zealand. Participants completed a mixed-methods questionnaire, co-designed with consumers, which investigated their perspectives about prognostic tests for ovarian cancer. Participants could opt-in to a 1-1.5-h online focus group to discuss their perspectives further. RESULTS: Thirty-three participants completed the online questionnaire. Participants perceived the potential advantages of the prognostic test outweighed the disadvantages, and 88 % would be 'very willing' or 'willing' to undergo prognostic testing if available. Nine participants took part in focus groups. We developed four themes from thematic analysis of these discussions: (1) Cancer journey and context, (2) Advantages and disadvantages of knowing prognosis, (3) The complexities of when to receive prognostic information, and (4) Communication and service delivery. CONCLUSION: Participants with ovarian cancer viewed prognostic testing positively. However, successful implementation will require a patient-centred approach that accommodates diverse preferences around how the test is introduced, and results are communicated.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Evans HE, Firriolo AM, Houweling R, et al. Evaluating patient perspectives about the acceptability of a novel prognostic gene expression signature for high grade serous ovarian cancer: The OTTA-SPOT study. Gynecol Oncol. 2025. PMID: 41351943. doi:10.1016/j.ygyno.2025.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。